Data gathered: December 6
Data Bits
Data Bits | Value / Change | Benchmark | |
---|---|---|---|
Job Posts | 88 0% |
|
|
Sentiment | 96 0% |
|
|
Webpage traffic | 38,000 -13.3% |
|
|
Employee Rating | 76 0% |
|
|
Linkedin Employees | 425 N/A |
|
|
4chan Mentions | 0% | N/A | |
Stocktwits Mentions | 7 -12.5% |
|
|
Stocktwits Subscribers | 10,986 -0% |
|
|
Twitter Followers | 299 0% |
|
|
News Mentions | 0% |
|
|
Reddit Mentions | 0% |
|
|
Business outlook | 72 0% |
|
In the news
Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), OrthoPediatrics (KIDS) and Axsome Therapeutics (AXSM)December 4 - TipRanks |
|
Maintaining Buy Rating on Axsome: Seasonal Prescription Dip Not a Long-Term ConcernDecember 4 - TipRanks |
|
Piper Sandler Remains a Buy on Axsome Therapeutics (AXSM)November 29 - TipRanks |
|
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Axsome Therapeutics (AXSM) and Cytokinetics (CYTK)November 28 - TipRanks |
|
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSMNovember 27 - GlobeNewswire |
|
11 Best Upside Stocks To Buy Right NowNovember 26 - Yahoo |
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

Price | $68.12 |
Target Price | Sign up |
Market Cap | $3.25B |
Dividend Yield | 0 |
Industry | Biotechnology |
Similar companies
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
---|---|---|---|---|---|
Q3 '23 | 53M | 91M | -39M | -62M | -56M |
Q2 '23 | 47M | 85M | -43M | -67M | -62M |
Q1 '23 | 95M | 83M | 6.8M | -11M | -2.6M |
Q4 '22 | 24M | 2.3M | -21M | -61M | -56M |
Q3 '22 | 14M | 1.9M | 12M | -45M | -40M |
Insider Transactions
Coleman Mark filed to sell 403,856 shares at $75.2. September 15 '23 |